<DOC>
	<DOC>NCT00378690</DOC>
	<brief_summary>Phase IIIb, Open-label, randomized, controlled multi-centre study. Induction therapy phase for 6 months where all subjects receive 2 ELIGARD depot injections. Those subjects with hormone responsive prostate cancer will be randomized and will receive either intermittent or continuous ELIGARD treatment for 36 months. Following this treatment period, subjects will enter a long-term follow-up period for 48 months.</brief_summary>
	<brief_title>A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>At study entry (visit 1): Written informed consent Male subjects aged &gt;=18 and &lt;80 years old Locally advanced (stage T3 or T4) prostate cancer or Relapsing prostate cancer following radical prostatectomy or,Relapsing prostate cancer following radiotherapy Gleason score of &gt;=6 ECOG performance status of 02. Life expectancy at least 5 years At randomization (visit 4): Two successive decreasing serum PSA levels &lt;=1 ng/ml At study entry (visit 1): Any suspected second primary tumors Evidence of metastatic disease Other malignancy within the last 5 years except Acute spinal cord compression, uni or bilateral ureteric obstruction Any concurrent biological response modifier therapy Concurrent chemotherapy Less than 1 year since any prior neoadjuvant or adjuvant hormonal therapy Less than 6 months since prior 5alpha reductase inhibitor treatment Other concurrent hormonal therapy Any concurrent radiotherapy Testosterone at screening &lt;= 1.7 mM or 50 ng/dL Clinically significant elevation of serum creatinine or liver enzymes Hypersensitivity to GnRH or other GnRH analogues or leuprorelin acetate Hypersensitivity to CASODEXÃ¢ 50 mg.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Specific Antigen</keyword>
</DOC>